Massively parallel sequencing (MPS) is an exciting technology that holds promise for enhancing the capabilities of the forensic DNA analyst. However, there are several challenges that confront implementation of an MPS system into the crime laboratory. These include: training and education on fundamentals of the chemistry, functionality and genetic marker systems, validation criteria and study design, policy and data procedure developments related to CODIS operations, and perceived admissibility and privacy issues. This four-part webinar series will address these and other areas of interest, providing foundational information on the two available MPS systems, covering platforms and chemistries, throughput, genetic markers, bioinformatics, validation requirements, applications, and potential admissibility issues.
This first webinar, "Understanding the Basic Technology," discusses the latest cutting edge information from the representatives, stakeholders and practitioners currently bringing this technology to fruition in the forensic science arena. The presentations and panel discussion include an overview of platforms - the Ion PGM™ and MiSeq™ systems- and their respective chemistries, including sample and library preparation. The discussions focus primarily on salient features of the platforms and systems so that forensic scientists may be better informed of the benefits of this promising new technology.
A certificate of completion is available for all who register and attend this webinar.
- Bruce Budowle
- Ernesto Guzman
- Mike Lelivelt
- Mark Wilson
- Seth Faith
- Pete Vallone
- Patricia Melton
Funding for this Forensic Technology Center of Excellence webinar has been provided by the National Institute of Justice, Office of Justice Programs, U.S. Department of Justice.
The opinions, findings, and conclusions or recommendations expressed in this webinar are those of the presenter(s) and do not necessarily reflect those of the U.S. Department of Justice.
Contact us at ForensicCOE@rti.org with any questions and subscribe to our newsletter for notifications.